You are viewing the site in preview mode

Skip to main content
Download PDF
Download ePub

Discovery of antimalarial drugs from secondary metabolites in actinomycetes culture library

Tropical Medicine and Health volume 52, Article number: 47 (2024) Cite this article

Abstract

Background

Natural products play a key role as potential sources of biologically active substances for the discovery of new drugs. This study aimed to identify secondary metabolites from actinomycete library extracts that are potent against the asexual stages of Plasmodium falciparum (P. falciparum).

Methods

Secondary metabolites from actinomycete library extracts were isolated from culture supernatants by ethyl acetate extraction. Comprehensive screening was performed to identify novel antimalarial compounds from the actinomycete library extracts (n = 28). The antimalarial activity was initially evaluated in vitro against chloroquine/mefloquine-sensitive (3D7) and-resistant (Dd2) lines of P. falciparum. The cytotoxicity was then evaluated in primary adult mouse brain (AMB) cells.

Results

Out of the 28 actinomycete extracts, 17 showed parasite growth inhibition > 50% at a concentration of 50 µg/mL, nine were identified with an IC50 value < 10 µg/mL, and seven suppressed the parasite significantly with an IC50 value < 5 µg/mL. The extracts from Streptomyces aureus strains HUT6003 (Extract ID number: 2), S. antibioticus HUT6035 (8), and Streptomyces sp. strains GK3 (26) and GK7 (27), were found to have the most potent antimalarial activity with IC50 values of 0.39, 0.09, 0.97, and 0.36 µg/mL (against 3D7), and 0.26, 0.22, 0.72, and 0.21 µg/mL (against Dd2), respectively. Among them, Streptomyces antibioticus strain HUT6035 (8) showed the highest antimalarial activity with an IC50 value of 0.09 µg/mL against 3D7 and 0.22 µg/mL against Dd2, and a selective index (SI) of 188 and 73.7, respectively.

Conclusion

Secondary metabolites obtained from the actinomycete extracts showed promising antimalarial activity in vitro against 3D7 and Dd2 cell lines of P. falciparum with minimal toxicity. Therefore, secondary metabolites obtained from actinomycete extracts represent an excellent starting point for the development of antimalarial drug leads.

Introduction

Malaria continues to be a life-threatening vector-borne disease globally, with Plasmodium falciparum (P. falciparum) being responsible for most clinical cases. Nearly half of the world’s population lives in areas that are at risk of malaria transmission i.e. in 85 malaria-endemic countries, infecting an estimated 247 million individuals, which resulted in 619,000 associated deaths in the year 2021 [1]. Between 2019 and 2021, 63,000 deaths were associated particularly to the COVID-19 pandemic-related disruption of services such as treatment, prevention, and diagnosis [1]. Sustainable elimination of malaria can be achieved through interventions such as successful treatment (artemisinin-based combination therapy [ACT]), integrated vector control, and immunization via vaccine [2,3,4]. Efforts have been made to minimize the occurrence of malaria and results have been achieved with ACT [5], vector control strategies [6], and vaccines [7]. However, the emergence of multidrug-resistant parasites and insecticide-resistant mosquitoes pose a threat to sustainable malaria control outcomes and remains elusive [8]. Artemisinin resistance has been reported in Rwanda, however, total resistance to artemisinin (RIII types) and treatment failure due to artemisinin have not been observed [9, 10]. Therefore, efforts to develop new antimalarial drug candidates with novel chemical scaffolds and mechanisms of action are needed to combat infections caused by the multidrug-resistant P. falciparum.

Streptomyces, the largest genus of actinomycetes, is a Gram-positive aerobic bacterium that is extensively found in nature and is an attractive source of natural antibiotics [11,12,13]. Over the last four decades, almost 50% of all antimicrobials were discovered from natural products [14]. Approximately 70% of the known antibiotics were derived from Streptomyces [15]. Discovery of bioactive substances from Streptomyces culture libraries is widely performed using traditional activity-based screening and physicochemical screening [16,17,18,19,20]. Currently, the World Health Organization (WHO) recommends a combination of actinomycetes-derived doxycycline and sulfadoxine-pyrimethamine for travelers to prevent malaria [1]. Streptomyces is also a rich resource for the discovery of antimalarial agents; for example, in recent studies, a phosphonate compound FR900098 from Streptomyces rubellomurinus [21, 22] and α-pyridone-containing iromycin analogs from Streptomyces sp. RBL-0292 [23] have been identified as potential antimalarial candidates. Here we report our findings on various natural product-based extracts and their active compounds that show antimalarial activity [10, 24, 25], arrest the strobilation of moon jellyfish Aurelia coerulea [26], and induce necrosis in potato tuber slices [27].

This study aimed to identify extracts from secondary metabolites of an actinomycete library that were potent against P. falciparum. The extracts were isolated and evaluated for their antimalarial activity in vitro against chloroquine/mefloquine-sensitive (3D7) and -resistant (Dd2) lines of P. falciparum. Firstly, 28 secondary metabolite extracts of actinomycetes were screened against 3D7, and the extracts with the IC50 value < 10 µg/mL, were further evaluated against the Dd2 cell line. Based on the therapeutic efficacy and toxicity, one extract was identified as a safe therapeutic agent that suppressed parasitemia with minimal toxicity and demonstrated an attractive parasite inhibitory effect.

Methods

Extraction and isolation of secondary metabolites of actinomycete

The actinomycete strains used in this study were obtained from the Hiroshima University type (HUT) Culture Collection. Other strains were obtained from the NITE Biological Resource Center (NBRC), the American Type Culture Collection (ATCC), the Japan Collection of Microorganisms (JCM), and the stocked culture library in our laboratory, including the potato scab pathogenic strains GK3, GK7, and GK18 [27] (Table S1). The strains were cultured in Yeast extract-Malt extract-Glucose (YMG) liquid media (0.4% yeast extract, 1.0% malt extract, and 0.4% d-glucose, pH 7.3) at 28 °C for 3 days. The culture broth was extracted twice with an equal volume of ethyl acetate (EtOAc). To obtain the crude extracts, the combined organic phase was dried over sodium sulfate, filtered, and concentrated in a vacuum.

Parasite culture

Blood stages of P. falciparum 3D7 and Dd2 cell lines were provided by Nagasaki University with support in part by NEKKEN Bio-Resource Center (NEKKEN BRC), Institute of Tropical Medicine, Nagasaki University as a part of the National BioResource Project (NBRP), MEXT, Japan. Human erythrocytes used for parasite culture were obtained from the Japan Red Cross Society (Registration No. 28J0060). The 3D7 and Dd2 parasites were cultivated in O + erythrocytes in 2% hematocrit in Roswell Park Memorial Institute (RPMI) 1640-based complete medium (CM) supplemented with 5% AB + human serum (prepared from plasma), 0.25% AlbuMax I (Gibco, Waltham, MA), 12.5 µg/mL gentamycin, and 200 mM hypoxanthine at 37 °C [28].

Cell culture

Primary adult mouse brain (AMB) cells were isolated and established at NEKKEN BRC, according to previously established methods [10]. Briefly, the primary cells, which were passaged several times to be adapted to in vitro conditions, were maintained in Minimum Essential Medium (MEM) (Wako Pure Chemicals Industrial Ltd, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin solution (100 units/mL penicillin G and 100 mg/mL streptomycin sulfate) (Wako Pure Chemicals Industrial Ltd) and incubated at 37 °C and 5% CO2. For the cytotoxicity assay, primary cells that had completed three passages were used.

Antimalarial growth inhibition assay

The antimalarial growth inhibition assay was performed as previously described [10]. The P. falciparum cultures (0.75% parasitemia and 2% hematocrit) were seeded onto a 96-well black plate with clear bottom (Thermo Fisher Scientific, Rochester, NY) and exposed to extracts which were at a final concentration of 50 µg/mL. The highest concentration of dimethyl sulfoxide (DMSO) solution (0.5%) did not interfere with the parasite growth. Chloroquine (CQ) (Sigma-Aldrich, St. Louis, MO) and artesunate (AS) (Shin Poong Pharm Co., Seoul, South Korea) were used as positive controls (5 µM-0.000028 nM) and DMSO < 0.5% was used as a negative control. The culture plates were incubated at 37 °C under mixed gas (5% O2, 5% CO2, and 90% N2) condition for 48 h. Each in vitro experiment was performed in duplicate and repeated twice. Inhibition of parasite growth was determined by dividing the parasitemia of the test samples by the average of the negative controls.

Antimalarial dose–response assay

SYBR Green—I (Lonza, Rockland, ME) assay technique was used to determine the concentration that inhibited 50% of the P. falciparum parasites (IC50). The antimalarial dose–response assay for the asexual stage of P. falciparum was performed as previously described with minor modifications [10, 29]. Briefly, a dose–response assay was performed for the samples that showed more than 50% inhibition in the first screening and an IC50 value (10(log(A/B) × (50 ‒ C)/(D ‒ C) +log(B)) was obtained, where A represents the lowest concentration at which the percentage inhibition was greater than 50%, B is the highest concentration value at which the percentage inhibition was less than 50%, C is the percentage inhibition value of the sample at concentration B, and D is the percentage inhibition value of the sample at concentration A. The extracts were distributed in six-fold serial dilution at 50 µg/mL–0.205 µg/mL. Furthermore, ten-fold serial dilutions were performed for some extracts (50 µg/mL–2.54 ng/mL). The final concentration of DMSO for all tested extracts, negative, and positive controls was adjusted to < 0.5%.

After 48 h of incubation with the extracts, RBCs were lysed by adding 100 µL of lysis buffer (20 mM Tris, 10 mM EDTA, 0.01% saponin (wt/vol), and 0.1% Triton X-100 (vol/vol), pH 7.5) and 1 × final concentration of SYBR Green—I into each well. The plates were incubated at room temperature for 1 h with gentle agitation. The relative fluorescence units (RFU) per well were then determined at 485–515 nm (filter) for 0.1 s per exposure using a multilabel plate reader (ARVO 1430; Perkin Elmer, Waltham, MA, USA).

Cytotoxicity assay

Cytotoxicity was evaluated as previously described [10]. Briefly, AMB cells (1 × 104 cells) were seeded in a 96-well plate (black plate with a clear bottom) and incubated at 37 °C in a CO2 incubator for 24 h. Three dilutions of the extracts (50 μg/mL–2.54 ng/mL) and their negative controls were added and the cells were further incubated for 48 h. To evaluate the cell viability (%), 10 µL of Alamar Blue solution (10%, Funakoshi Co., Tokyo, Japan) was added into each well and the cells were incubated for 2 h at 37 °C. The fluorescence intensity of each well was measured at 590 nm for 0.1 s per exposure using a multi-label plate reader. The 50% cytotoxic concentration (CC50), the concentration of drug required to reduce cell viability by 50% (10(log(A/B) × (50 ‒ C)/(D ‒ C) +log(B)), was determined for samples that showed less than 50% viability in the initial screening, where A represented the lowest concentration value at which the percentage viable cell showed greater than 50%, B was the highest concentration value at which the percentage viable cell showed less than 50%, C was the percentage viable cell value of the sample at a concentration B, and D was the percentage viable cell value of the sample at a concentration A. All assays were performed twice independently in duplicate wells. The IC50 and CC50 values were used as indicators of in vitro antimalarial activity and cytotoxicity, respectively. Curves and figures were plotted using GraphPad Prism 6 software (GraphPad Software Inc., San Diego, CA, USA). The selectivity index (SI) was obtained by dividing the CC50 value by the IC50 value.

Ethics statement

The Research plan for this project, involving human RBCs and plasma (serum), was approved by the Research Ethics Committee of the Institute of Tropical Medicine, Nagasaki University (Approval No. 170921176-6).

Results

Metabolic extraction/ isolation of secondary metabolite extracts of actinomycete

Twenty-eight actinomycete strains (Table S1) were cultured in YMG medium (10 mL) at 28 °C for 3 days. Each aliquot of these pre-cultures (1 mL) was transferred to 100 mL of YMG liquid medium and incubated at 28 °C for 3 days. The culture supernatants were extracted twice with equal volume of ethyl acetate, and the combined organic phases were dried with Na2SO4, filtered, and concentrated in vacuo to obtain crude extracts. The extracts (average of 40 mg extracts per 100 mL of culture) were dissolved in DMSO to obtain a stock solution of 10 mg/mL and then subjected to in vitro antimalarial assay.

In vitro screening of antimalarial activity and cytotoxicity assay of the 28 secondary metabolites of actinomycetes

In vitro, antimalarial assay was performed to evaluate the antimalarial effects of the 28 extracts derived from secondary metabolites of actinomycetes. A comprehensive screening system was established for the extracts against chloroquine (CQ)/mefloquine (MQ)-sensitive (3D7) and -resistant (Dd2) laboratory cell lines of P. falciparum. Firstly, the primary screening of the extracts was performed using a concentration of 50 µg/mL. This screening of 28 secondary metabolites of actinomycete yielded 17 extracts that demonstrated parasite inhibition > 50% (Fig. 1). To determine the IC50 value, the dose–response assay was further carried out for the 17 extracts (parasite inhibition > 50%), of which, 9 extracts with an IC50 < 10 µg/mL were identified, 7 of which suppressed the parasite significantly with an IC50 < 5 µg/mL (Table 1, Fig. 2). Among them, Streptomyces aureus strain HUT6003 (Extract ID number: 2), Streptomyces antibioticus HUT6035, (ID 8) Streptomyces sp. strain GK3, (ID 26) and GK7 (ID 27) demonstrated potent antimalarial activity against P. falciparum 3D7, with IC50 values 0.39, 0.09, 0.97, and 0.36 µg/mL, respectively. In addition, cell viability was evaluated to study the cytotoxicity of the extracts and 16 extracts showed toxicity (< 50% cell viability) at a concentration of 50 µg/mL. Dose-titration assays were further carried out for the 16 extracts (Fig. 3) and the resulting CC50 values of the extracts were determined (Fig. 4). Streptomyces verne strain HUT6034 (ID 7) did not show toxicity (CC50 > 50 µg/mL). The extract obtained from S. antibioticus strain HUT6035 (ID 8) was the safest out of the four potent extracts examined, with a CC50 value of 16.3 µg/mL. The selectivity indices (SI; CC50/IC50) of S. aureus strain HUT6003, (ID 2) S. antibioticus HUT6035, (ID 8) Streptomyces sp. strains GK3, (ID 26) and GK7 (ID 27) were 0.9, 188, 1.13, and 0.88 3D7, respectively (Figs. 5, 6, 7). In addition, S. verne strain HUT6034 [7] displayed an SI value > 14.83. Further antimalarial assays were performed using the extracts that exhibited the lowest IC50 on the P. falciparum Dd2 cell line. Four strains, namely, (S. aureus strain HUT6003, (ID 2) S. antibioticus HUT6035, (ID 8) Streptomyces sp. strains GK3 (ID 26) and GK7 (ID 27) showed potent activity against Dd2, and their IC50 and SI were 0.26, 0.22, 0.72, and 0.21 µg/mL, and 1.34, 73.7, 1.51, and 1.45, respectively (Table 1). Among the four extracts, S. antibioticus strain HUT6035 (ID 8) was the most active against both 3D7 and Dd2.

Fig. 1
figure 1

In vitro antimalarial screening of 28 extracts derived from secondary metabolites of actinomycetes. The primary in vitro antimalarial screening was performed against P. falciparum 3D7 strain using a concentration of 50 µg/mL. The x-axis represents ID number of the extracts, and the y-axis represents parasitemia inhibition. The circular dots represent the percentage of parasite inhibition caused by the extracts, including 17 extracts with parasitemia inhibition >50%. The value of parasitemia inhibition caused by the extracts (circle dots) was obtained from two independent experiments performed in duplicate

Full size image
Table 1 In vitro antimalarial activity and cytotoxicity of actinomycete secondary metabolite extracts
Full size table
Fig. 2
figure 2

Dose-response in vitro antimalarial assay against P. falciparum 3D7. To determine the IC50 value, a dose-response assay was performed using the extracts that demonstrated parasite growth inhibition >50%. The x-axis represents the ID number of the extracts and the y-axis represents IC50. Error bars indicate the mean IC50 ± SD of two independent experiments performed in duplicate

Full size image
Fig. 3
figure 3

In vitro cytotoxicity screening of 28 extracts from secondary metabolites from actinomycetes. The primary in vitro cytotoxicity screening was performed against Adult Mouse Brain (AMB) cells at a concentration of 50 µg/mL. The x-axis represents ID number of the extracts and the y-axis represents viable cells. The circular dots represent the percentage of viable cells in the extracts. The cell viability value of the extracts (circles) was obtained from two independent experiments performed in duplicate

Full size image
Fig. 4
figure 4

Dose-titration in vitro cytotoxicity assay of AMB cells. A dose-titration assay was performed using the extracts that demonstrated cell viability <50% to determine the CC50 value. The x-axis represents the ID number of the extracts and the y-axis represents CC50. Error bars indicate mean CC50 ± SD of two independent experiments performed in duplicate

Full size image
Fig. 5
figure 5

IC50, CC50, and SI of hit extracts against 3D7 and AMB cells. The x-axis represents the ID numbers of the extracts, whereas the y-axis represents the values. Error bars indicate the mean CC50/IC50 ± SD of two independent experiments performed in duplicate

Full size image
Fig. 6
figure 6

Antimalarial dose-response and dose-titration cytotoxicity of selected extracts. A Streptomyces antibioticus strain HUT6003 (ID 2), B Streptomyces verne strain HUT6034 (ID 7), C Streptomyces sp. GK3 (ID 26) and D Streptomyces sp. GK7 (ID 27). The blue circle represents parasite inhibition (%) from the dose-response assay, whereas the red circle represents cell viability (%) from the dose-titration assay. Error bars indicate the mean parasite inhibition (%) /cell viability (%) ± SD of two independent experiments performed in duplicate

Full size image
Fig. 7
figure 7

Antimalarial activity and cytotoxicity of Streptomyces antibioticus strain HUT6035 (ID 8). A Antimalarial dose-response assay. The blue circle represents parasite inhibition (%). B Cytotoxicity dose-titration assay. The red circle represents cell viability (%). Error bars indicate parasite inhibition (%) /cell viability (%) ± SD of two independent experiments performed in duplicate

Full size image

Discussion

Antimalarial treatments are hampered by the emergence of multidrug-[30] and insecticide-resistant mosquitoes [31]. Antibiotics are attractive agents for the treatment of malaria and have been investigated for a long time. Among them, tetracycline plays a key role [32]. Several Streptomyces-derived macrolide antibiotics have been investigated for antimalarial activity [33]. The WHO recommends Streptomyces-derived antibiotics such as doxycycline, clindamycin, and a combination of sulfadoxine-pyrimethamine for travelers to prevent malaria [1]. Therefore, this study focused on the secondary metabolites obtained from actinomycetes-derived extracts to develop new and effective antimalarial drugs. In the present study, the secondary metabolites of actinomycetes were isolated and investigated against the 3D7 and Dd2 strains of P. falciparum. Our study showed that extracts from Streptomyces aureus strain HUT6003 (ID 2), S. antibioticus HUT6035 (ID 8), Streptomyces sp. strains GK3 (ID 26), and GK7 (ID 27) had the most potent antimalarial activity and displayed high inhibitory activity towards asexual blood-stage malaria. Among these, Streptomyces antibioticus strain HUT6035 displayed potent antimalarial activity, selectively inhibiting parasite growth with minimal toxicity, suggesting that it could be a hit extract.

Natural microbial products are key sources for drug discovery. Several macrolide antibiotics have been produced by Streptomyces, with potent activity against certain cancers, gram-positive bacteria, fungi [34, 35], methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumonia (PRSP) [36]. S. antibioticus-derived macrolide-containing antibiotics (boromycin) have recently been reported to exhibit asexual and sexual blood-stage antimalarial activity [37]. In this study, Streptomyces aureus strain HUT6003 (ID 2)and antibioticus HUT6035 (ID 8) demonstrated potent antimalarial activity. However, strain HUT6003 (ID 2) displayed toxicity with a CC50 value of 0.35 μg/mL. Therefore, strain HUT6035 (ID 8) would be the most promising extract for further investigation due to its efficacy and minimal toxicity. This is the first study to report the antimalarial activity of S. aureus HUT6003 (ID 2) and S. antibioticus HUT6035 (ID 8).

A 17-membered carbocyclic polyketide, lankacidin C (LC), exhibits antimicrobial and antitumor activities. LC inhibit microbial protein synthesis and exhibit synergistic activity in coordination with lankamycin, another polyketide antibiotic produced in the same strain [38, 39]. LC has considerable antitumor activity with a paclitaxel-like mode of action [40,41,42,43]. In our study, the in vitro antimalarial activities of Streptomyces sp. strains GK3 (ID 26) and GK7 (ID 27) were observed. However, both strains were toxic to the cells with a CC50 value of 1.1 and 0.31 µg/mL, respectively.

Streptomyces antibioticus strain HUT6035 (ID 8) was selected for further investigation because of its potent antimalarial activity against both 3D7 and Dd2 cell lines, moderate toxicity, and high SI. Therefore, additional investigations of its antimalarial activity will be performed for hit-to-lead drug development after the isolation of different fractions and active compounds from the culture of S. antibioticus strain HUT6035 (ID 8). Although S. aureus strain HUT6003 (ID 2) and Streptomyces sp. strains GK3 (ID 26) and GK7 (ID 27) displayed good antimalarial activity, their toxicity is a barrier to further investigation. Moreover, their parasite-killing effects may be due to toxicity.

Extracts derived from Streptomyces are promising antimalarial agents and should be further investigated by identifying the fractions and isolating the active compounds. Additional investigations of in vitro and in vivo assays are required to determine the efficacy of the isolated compounds and to understand how these compounds could be used to treat malaria. Our results confirmed that extracts derived from the secondary metabolites of actinomycetes could be a rich source of antimalarial compounds. Therefore, the continuous exploration of new antimalarial compounds from Streptomyces will be our next target.

The mechanism of action of the candidate extract Streptomyces antibioticus HUT6035 (ID 8) is still unknown, however, it was active against the sensitive (3D7) and resistant (Dd2) strains with a resistance index (RI) of 2.44, which is very close to the RI of artesunate 1.24 (Table 1) and far better than that of chloroquine (CQ) 14.24, suggesting that the mechanisms of action are different from those of CQ. In addition, according to previous reports, the mechanisms of action of candidate extracts may be related to their binding to DNA, which interferes with replication and transcription (44,45,46). This is a possible mechanism of action. Therefore, further investigations are required to determine the mechanism of action after identifying the active compounds.

Our in vitro drug assay methods were designed to target the early stage of the asexual life cycle, suggesting that the candidate extracts inhibited the parasite and distorted the morphology of the cells during the ring and late trophozoite stages.

Conclusions

Thus, we demonstrated the antimalarial activity of different extracts derived from secondary metabolites from the actinomycetes library against the 3D7 and Dd2 strains of P. falciparum. Our results suggest that secondary metabolites of actinomycetes are potential natural sources of antimalarial agents.

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding authors upon reasonable request.

Abbreviations

ACT:

Artemisinin-base combination therapy

AMB:

Adult mouse brain

AS:

Artesunate

ATCC:

American type culture collection

CC50 :

50% Cytotoxic concentration

CM:

Complete media

CQ:

Chloroquine

DMSO:

Dimethyl sulfoxide

EtOAc:

Ethyl acetate

FBS:

Fetal bovine serum

HUT:

Hiroshima University type

IC50 :

50% Inhibitory concentration

iRBC:

Infected RBC

JCM:

Japan collection of microorganisms

LC:

Lankacidin C

MQ:

Mefloquine

MRSA:

Methicillin-resistant Staphylococcus aureus

NBRC:

NITE Biological Resource Center

NBRP:

National BioResource Project

NEKKEN BRC:

NEKKEN Bio-Resource Center

P.  falciparum :

Plasmodium falciparum

PRSP:

Penicillin-resistant Streptococcus pneumonia

RFU:

Relative fluorescence unit

RI:

Resistance index

SI:

Selectivity index

VRE:

Vancomycin-resistant Enterococcus

WHO:

World Health Organization

YMG:

Yeast extract-Malt extract-Glucose

References

  1. <WHO WORLD MALARIA REPORT 2022.pdf>.

  2. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):215–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395(10233):1345–60.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 2017;14(11): e1002456.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malar J. 2019;18(1):93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ngufor C, Govoetchan R, Fongnikin A, Vigninou E, Syme T, Akogbeto M, et al. Efficacy of broflanilide (VECTRON T500), a new meta-diamide insecticide, for indoor residual spraying against pyrethroid-resistant malaria vectors. Sci Rep. 2021;11(1):7976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. <World Malaria Report 2021.pdf>.

  8. Talman AM, Clain J, Duval R, Menard R, Ariey F. Artemisinin bioactivity and resistance in malaria parasites. Trends Parasitol. 2019;35(12):953–63.

    Article  CAS  PubMed  Google Scholar 

  9. Burgert L, Zaloumis S, Dini S, Marquart L, Cao P, Cherkaoui M, et al. Parasite–host dynamics throughout antimalarial drug development stages complicate the translation of parasite clearance. Antimicrob Agents Chemother. 2021;65(4):e01539-e1620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Teklemichael AA, Mizukami S, Toume K, Mosaddeque F, Kamel MG, Kaneko O, et al. Anti-malarial activity of traditional Kampo medicine Coptis rhizome extract and its major active compounds. Malar J. 2020;19(1):204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chen J, Xu L, Zhou Y, Han B. Natural products from actinomycetes associated with marine organisms. Mar Drugs. 2021;19(11):629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ahmad SJ, Abdul Rahim MBH, Baharum SN, Baba MS, Zin NM. Discovery of antimalarial drugs from streptomycetes metabolites using a metabolomic approach. J Trop Med. 2017;2017:2189814.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.

    Article  CAS  PubMed  Google Scholar 

  15. De La Hoz-Romo MC, Diaz L, Villamil L. Marine actinobacteria a new source of antibacterial metabolites to treat acne vulgaris disease—a systematic literature review. Antibiotics (Basel). 2022;11(7):965.

    Article  PubMed  Google Scholar 

  16. Takahashi Y, Nakashima T. Actinomycetes, an inexhaustible source of naturally occurring antibiotics. Antibiotics (Basel). 2018;7(2):45.

    Article  PubMed  Google Scholar 

  17. Lacey HJ, Rutledge PJ. Recently discovered secondary metabolites from Streptomyces Species. Molecules. 2022;27(3):887.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ser HL, Tan LT, Law JW, Chan KG, Duangjai A, Saokaew S, et al. Focused review: cytotoxic and antioxidant potentials of mangrove-derived Streptomyces. Front Microbiol. 2017;8:2065.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Law JW, Chan KG, He YW, Khan TM, Ab Mutalib NS, Goh BH, et al. Diversity of Streptomyces spp. from mangrove forest of Sarawak (Malaysia) and screening of their antioxidant and cytotoxic activities. Sci Rep. 2019;9(1):15262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Park HS, Nah HJ, Kang SH, Choi SS, Kim ES. Screening and isolation of a novel polyene-producing streptomyces strain inhibiting phytopathogenic fungi in the soil environment. Front Bioeng Biotechnol. 2021;9: 692340.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999;285(5433):1573–6.

    Article  CAS  PubMed  Google Scholar 

  22. Eliot AC, Griffin BM, Thomas PM, Johannes TW, Kelleher NL, Zhao H, et al. Cloning, expression, and biochemical characterization of Streptomyces rubellomurinus genes required for biosynthesis of antimalarial compound FR900098. Chem Biol. 2008;15(8):765–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kimura SI, Watanabe Y, Shibasaki S, Shinzato N, Inahashi Y, Sunazuka T, et al. New antimalarial iromycin analogs produced by Streptomyces sp. RBL-0292. J Antibiot (Tokyo). 2024;77:272–7.

    Article  CAS  PubMed  Google Scholar 

  24. Hashim Y, Toume K, Mizukami S, Ge YW, Taniguchi M, Teklemichael AA, et al. Phenylpropanoid conjugated iridoids with anti-malarial activity from the leaves of Morinda morindoides. J Nat Med. 2021;75(4):915–25.

    Article  CAS  PubMed  Google Scholar 

  25. Hashim Y, Toume K, Mizukami S, Kitami T, Taniguchi M, Teklemichael AA, et al. Phenylpropanoid-conjugated iridoid glucosides from leaves of Morinda morindoides. J Nat Med. 2022;76(1):281–90.

    Article  CAS  PubMed  Google Scholar 

  26. Misaki Y, Hirashima T, Fujii K, Hirata A, Hoshino Y, Sumiyoshi M, et al. 4-Methoxy-2,2′-bipyrrole-5-carbaldehyde, a biosynthetic intermediate of bipyrrole-containing natural products from the Streptomyces culture, arrests the strobilation of moon jellyfish Aurelia coerulea. Front Mar Sci. 2023;10:1198136.

    Article  Google Scholar 

  27. Cao Z, Khodakaramian G, Arakawa K, Kinashi H. Isolation of borrelidin as a phytotoxic compound from a potato pathogenic streptomyces strain. Biosci Biotechnol Biochem. 2012;76(2):353–7.

    Article  CAS  PubMed  Google Scholar 

  28. Trager W, Jenson JB. Cultivation of malarial parasites. Nature. 1978;273(5664):621–2.

    Article  CAS  PubMed  Google Scholar 

  29. Mosaddeque F, Mizukami S, Kamel MG, Teklemichael AA, Dat TV, Mizuta S, et al. Prediction model for antimalarial activities of hemozoin inhibitors by using physicochemical properties. Antimicrob Agents Chemother. 2018;62(5):e02424-e2517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Su XZ, Lane KD, Xia L, Sá JM, Wellems TE. Plasmodium genomics and genetics: new insights into malaria pathogenesis, drug resistance, epidemiology, and evolution. Clin Microbiol Rev. 2019;32(4):e00019-19.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Paton DG, Probst AS, Ma E, Adams KL, Shaw WR, Singh N, et al. Using an antimalarial in mosquitoes overcomes Anopheles and Plasmodium resistance to malaria control strategies. PLoS Pathog. 2022;18(6): e1010609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gaillard T, Madamet M, Tsombeng FF, Dormoi J, Pradines B. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malar J. 2016;15(1):556.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Arsic B, Barber J, Cikos A, Mladenovic M, Stankovic N, Novak P. 16-membered macrolide antibiotics: a review. Int J Antimicrob Agents. 2018;51(3):283–98.

    Article  CAS  PubMed  Google Scholar 

  34. Jaroszewicz W, Bielanska P, Lubomska D, Kosznik-Kwasnicka K, Golec P, Grabowski L, et al. Antibacterial, antifungal and anticancer activities of compounds produced by newly isolated Streptomyces strains from the Szczelina Chocholowska Cave (Tatra Mountains, Poland). Antibiotics (Basel). 2021;10(10):1212.

    Article  CAS  PubMed  Google Scholar 

  35. Bao Y, Li H, Dong Y, Duan H, Li H, Li W. Genome-guided discovery of antifungal filipins from a deep-sea-derived Streptomyces antibioticus. J Nat Prod. 2022;85(2):365–74.

    Article  CAS  PubMed  Google Scholar 

  36. Sharma M, Manhas RK. Purification and characterization of actinomycins from Streptomyces strain M7 active against methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus. BMC Microbiol. 2019;19(1):44.

    Article  PubMed  PubMed Central  Google Scholar 

  37. de Carvalho LP, Groeger-Otero S, Kreidenweiss A, Kremsner PG, Mordmuller B, Held J. Boromycin has rapid-onset antibiotic activity against asexual and sexual blood stages of Plasmodium falciparum. Front Cell Infect Microbiol. 2021;11: 802294.

    Article  PubMed  Google Scholar 

  38. Auerbach T, Mermershtain I, Davidovich C, Bashan A, Belousoff M, Wekselman I, et al. The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics. Proc Natl Acad Sci U S A. 2010;107(5):1983–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Belousoff MJ, Shapira T, Bashan A, Zimmerman E, Rozenberg H, Arakawa K, et al. Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit. Proc Natl Acad Sci U S A. 2011;108(7):2717–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ayoub AT, Abou El-Magd RM, Xiao J, Lewis CW, Tilli TM, Arakawa K, et al. Antitumor activity of lankacidin group antibiotics is due to microtubule stabilization via a paclitaxel-like mechanism. J Med Chem. 2016;59(20):9532–40.

    Article  CAS  PubMed  Google Scholar 

  41. Ayoub AT, Elrefaiy MA, Arakawa K. Computational prediction of the mode of binding of antitumor lankacidin C to tubulin. ACS Omega. 2019;4(2):4461–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Muslimin R, Nishiura N, Teshima A, Do KM, Kodama T, Morita H, et al. Chemoenzymatic synthesis, computational investigation, and antitumor activity of monocyclic lankacidin derivatives. Bioorg Med Chem. 2022;53: 116551.

    Article  CAS  PubMed  Google Scholar 

  43. Ayoub AT, Nishiura N, Teshima A, Elrefaiy MA, Muslimin R, Do KM, et al. Bioinspired computational design of lankacidin derivatives for improvement in antitumor activity. Future Med Chem. 2022;14(19):1349–60.

    Article  CAS  PubMed  Google Scholar 

  44. Lo Y-S, Tseng W-H, Chuang C-Y, Hou M-H. The structural basis of actinomycin D-binding induces nucleotide flipping out, a sharp bend and a left-handed twist in CGG triplet repeats. Nucleic Acids Res. 2013;41(7):4284–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Koba M, Konopa J. Actinomycin D and its mechanisms of action. Postepy Hig Med Dosw (Online). 2005;59:290–8.

    PubMed  Google Scholar 

  46. Lu DF, Wang YS, Li C, Wei GJ, Chen R, Dong DM, et al. Actinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells. Int J Clin Exp Med. 2015;8(2):1904–11.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was conducted in part at the Joint Usage/Research Center on Tropical Disease, Institute of Tropical Medicine (NEKKEN), Nagasaki University.

Funding

This study was conducted at the Joint Usage/Research Center on Tropical Diseases, Institute of Tropical Medicine, Nagasaki University (2021-Ippan-32, 2022-Ippan-33, and 2023-Ippan-27).

Author information

Author notes

  1. Awet Alem Teklemichael and Aiko Teshima contributed equally to this work.

Authors and Affiliations

  1. Department of Immune Regulation, SHIONOGI Global Infectious Diseases Division, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Nagasaki, Japan

    Awet Alem Teklemichael, Mayumi Taniguchi & Shusaku Mizukami

  2. Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, Japan

    Aiko Teshima, Asahi Hirata, Momoko Akimoto, Takashi Fujimura & Kenji Arakawa

  3. Hiroshima Research Center for Healthy Aging (HiHA), Hiroshima University, Higashi-Hiroshima, Hiroshima, Japan

    Aiko Teshima, Asahi Hirata, Momoko Akimoto, Takashi Fujimura & Kenji Arakawa

  4. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Nagasaki, Japan

    Mayumi Taniguchi, Fuyuki Tokumasu & Shusaku Mizukami

  5. Department of Plant Protection, College of Agriculture, Bu-Ali Sina University, Hamedan, Iran

    Gholam Khodakaramian

  6. Department of Cellular Architecture Studies, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Nagasaki, Japan

    Fuyuki Tokumasu

  7. Department of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan

    Fuyuki Tokumasu

Authors
  1. Awet Alem Teklemichael
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Aiko Teshima
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Asahi Hirata
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Momoko Akimoto
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Mayumi Taniguchi
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Gholam Khodakaramian
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Takashi Fujimura
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Fuyuki Tokumasu
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Kenji Arakawa
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Shusaku Mizukami
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

A.A.T., A.T., K.A., and S.M. conceived and designed the experiments. A. A. T., A. T., A. H., M. A., M. T., G. K., T. F., K. A., and S. M. performed the experiments. A.A.T., A.T., F.T., K.A., and S.M. analyzed and interpreted the data. A.A.T., A.T., K.A., and S.M. wrote the manuscript. All the authors have read and approved the final version of the manuscript.

Corresponding authors

Correspondence to Kenji Arakawa or Shusaku Mizukami.

Ethics declarations

Ethics approval and consent to participate

Human RBCs and plasma were obtained and used after obtaining approval from the Institutional Ethical Review Board of the Institute of Tropical Medicine, Nagasaki University.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest. Nagasaki University and Shionogi & Co., Ltd. launched the Shionogi Global Infectious Diseases Division at the Institute of Tropical Medicine, Nagasaki University. Although the authors of the division receive salaries from Nagasaki University, Shionogi & Co., Ltd. allocates the budget to Nagasaki University for their employment. However, Shionogi & Co., Ltd. did not play a role in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teklemichael, A.A., Teshima, A., Hirata, A. et al. Discovery of antimalarial drugs from secondary metabolites in actinomycetes culture library. Trop Med Health 52, 47 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s41182-024-00608-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s41182-024-00608-1

Keywords

Tropical Medicine and Health

ISSN: 1349-4147

Contact us